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sBACKGROUND: Single-nucleotide polymorphisms (SNPs) in genes involved in DNA repair are good candidates to be tested as
phenotypic modifiers for carriers of mutations in the high-risk susceptibility genes BRCA1 and BRCA2. The base excision repair (BER)
pathway could be particularly interesting given the relation of synthetic lethality that exists between one of the components of the
pathway, PARP1, and both BRCA1 and BRCA2. In this study, we have evaluated the XRCC1 gene that participates in the BER pathway,
as phenotypic modifier of BRCA1 and BRCA2.
METHODS: Three common SNPs in the gene, c.-77C4T (rs3213245) p.Arg280His (rs25489) and p.Gln399Arg (rs25487) were
analysed in a series of 701 BRCA1 and 576 BRCA2 mutation carriers.
RESULTS: An association was observed between p.Arg280His-rs25489 and breast cancer risk for BRCA2 mutation carriers, with rare
homozygotes at increased risk relative to common homozygotes (hazard ratio: 22.3, 95% confidence interval: 14.3–34, Po0.001).
This association was further tested in a second series of 4480 BRCA1 and 3016 BRCA2 mutation carriers from the Consortium of
Investigators of Modifiers of BRCA1 and BRCA2.
CONCLUSIONS AND INTERPRETATION: No evidence of association was found when the larger series was analysed which lead us to
conclude that none of the three SNPs are significant modifiers of breast cancer risk for mutation carriers.
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Germ-line mutations in the BRCA1 and BRCA2 genes confer a high
lifetime risk of developing breast or ovarian cancer. Estimates of
the cumulative risk of breast cancer to age 70 vary from 40 to 85%,
depending on the study (Easton et al, 1995; Ford et al, 1998;
Antoniou et al, 2003; Chen et al, 2006; Milne et al, 2008).
Environmental and other genetic factors (risk modifiers) are likely
to explain these differences, at least in part. The few reliable
genetic associations that have been reported to date, have all come
from the Consortium of Investigators of Modifiers of BRCA1/2
(CIMBA) initiative, which was set up to provide large samples of
mutation carriers to reliably assess even modest associations with
single-nucleotide polymorphisms (Chenevix-Trench et al, 2007).
The CIMBA has assessed risk in BRCA1/2 carriers for various SNPs
in genes that had been previously found to be associated with
increased breast cancer risk in the general population, mostly via
genome-wide association studies (Antoniou et al, 2008, 2009).
However, the first evidence of a modifier came from a candidate
gene approach studying the RAD51 gene, which interacts directly
with BRCA1 and BRCA2. All three genes participate in the DNA
double-strand break repair by the homologous recombination
pathway. Results from the CIMBA study suggested an increased
risk of breast cancer for BRCA2 mutation carriers with two copies
of the ‘C’ allele at the 135G-C SNP (rs 1801320) in the 50
untranslated region of RAD51 (Antoniou et al, 2007). This result
suggests that other genes involved in DNA repair could as also
function as cancer risk modifiers for BRCA1 and BRCA2 mutation
carriers.
It has been proven that a deficiency in the base excision repair
(BER) pathway can give rise to stalling of the replication fork and
accumulation of double-strand DNA breaks which, in the presence
of a defective BRCA1 or BRCA2 background, could persist and lead
to cell cycle arrest or cell death (Farmer et al, 2005). This synthetic
lethality interaction led us to hypothesise that SNPs in genes
participating in this pathway could be potential modifiers of
cancer risk in BRCA1 and BRCA2 mutation carriers. The XRCC1
gene is involved in the BER pathway and its association with
different types of cancer have been extensively investigated, with
no conclusive results (Kiyohara et al, 2006; Figueroa et al, 2007;
Naccarati et al, 2007; Doecke et al, 2008; Fontana et al, 2008;
McWilliams et al, 2008; Chang et al, 2009; Zhai et al, 2009). Four
SNPs in XRCC1, three of them leading to amino acid changes
(p.Arg194Trp, p.Arg280His and p.Gln399Arg) and one in the
promoter region (c.-77C4T) are within the most common in
terms of minor allele frequency, and a potential effect on the
function of the XRCC1 protein has been suggested for them,
although no clear association with breast cancer risk has been
reported (Takanami et al, 2005; Hao et al, 2006; Sterpone et al,
2009; Sterpone et al, 2010). Nevertheless, the specific interaction
mentioned above suggests that common variation in XRCC1 may
have an effect on breast cancer risk for BRCA1 or BRCA2 mutation
carriers. In this study, we aimed to assess this hypothesis for the
three most studied SNPs in XRCC1, c.-77C4T (rs3213245)
p.Arg280His (rs25489) and p.Gln399Arg (rs25487) using a two-
stage approach.
MATERIAL AND METHODS
Patients
Eligible subjects were female carriers of deleterious mutations in
BRCA1 or BRCA2 aged Z18 years from which complete
information about year of birth, mutation description, age at last
follow-up, ages at breast and or ovarian cancer diagnosis and age
or date of prophylactic mastectomy was available (Antoniou et al,
2008). A total of 14 collaborating CIMBA studies from 10
countries, contributed genotypes for the study. Details of each
study along with the numbers of samples included from each are
provided in Table 1. The CNIO, ICO and MBCSG studies
participated in the first stage in which the three SNPs,
rs3213245, rs25489 and rs25487 were analysed and a potential
association between rs25489 and breast cancer risk was identified.
The remaining CIMBA samples were included in the stage II
analysis and contributed genotypes for rs25489 only.
Subjects who reported having ethnicity other than white
European were excluded from the analyses. This gave a total of
7496 female mutation carriers (4480 with mutations in BRCA1 and
3016 with mutations in BRCA2), 3891 of whom had been diagnosed
with breast cancer (2293 and 1598 with mutations in BRCA1 and
BRCA2, respectively). All carriers participated in clinical and/or
research studies at the host institution under IRB-approved
protocols.
Genotyping
The genotyping platform used by each study is detailed in Table 1.
For 11 studies, matrix assisted laser desorption/ionisation time of
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primer extension products using Sequenom’s MassARRAY system
and iPLEX technology (Sequenom, San Diego, CA, USA). The
design of oligonucleotides was carried out according to the
guidelines of Sequenom and performed using MassARRAY Assay
Design software (version 3.1). Three studies carried out genotyping
by nuclease assay (Taqman). Taqman genotyping reagents were
designed by Applied Biosystems (http://www.appliedbiosystems.
com/) as Assays-by-Design. Genotyping was performed using the
ABI PRISM 7900HT, 7700 or 7500 Sequence Detection Systems
according to manufacturer’s instructions. All studies complied
with CIMBA genotyping quality control standards (http://
www.srl.cam.ac.uk/consortia/cimba/eligibility/eligibility.html).
Statistical analysis
To test for departure from Hardy–Weinberg equilibrium a single
individual was randomly selected from each family and Pearson’s
w
2-test (1d.f.) was applied to genotypes from this set of
individuals. The association of the SNPs with breast cancer risk
was assessed by estimating hazard ratios (HRs) and their
corresponding 95% confidence intervals (CIs) using weighted
multivariable Cox proportional hazards regression with robust
estimates of variance (Antoniou et al, 2005). For each mutation
carrier, we modelled the time to diagnosis of breast cancer from
birth, censoring at the first of the following events: bilateral
prophylactic mastectomy, breast cancer diagnosis, ovarian cancer
diagnosis, death and date last know to be alive. Subjects were
considered affected if their age at censoring corresponded to their
age at diagnosis of breast cancer and unaffected otherwise.
Weights were assigned separately for carriers of mutations in
BRCA1 and BRCA2, by age (o25, 25–29, 30–34, 35–39, 40–44,
45–49, 50–54, 55–59, 60–64, 65–69, X70) and affection status, so
that the weighted observed incidences in the sample agreed with
established estimates for mutation carriers (Antoniou et al, 2003).
This approach has been shown to adjust for the bias inherent in
the oversampling of affected women because of the ascertainment
criteria used (Antoniou et al, 2005).
We considered log-additive and co-dominant genetic models
and tested for departure from HR¼1 by applying a Wald test
based on the log HR estimate and its standard error. Additional
independent variables included in all analyses were year of birth
(o1930, 1930–1939, 1940–1949, 1950–1959, 1960–1969, X1970),
study centre and country. Heterogeneity in HRs by study centre
was assessed by the w
2 equivalent of a Wald test based on the
interaction terms for the per-allele effect by centre (on 13d.f.).
A number of sensitivity analyses were applied, including censoring
at bilateral prophylactic oophorectomy (BPO), adjusting for BPO
(as a time-varying covariate) and excluding prevalent cases,
defined as those diagnosed more than 3 years before the interview.
All statistical analyses were carried out using Stata: Release 10
(StataCorp. 2007. Stata Statistical Software: Release 10.0. College
Station, TX, USA: Stata Corporation LP). Robust estimates of
variance were calculated using the cluster sub-command, applied
to an identifier variable unique to each family.
RESULTS AND DISCUSSION
In this study, we aimed to evaluate the role of three of the most
studied SNPs in the XRCC1 gene, c.-77C4T (rs3213245)
p.Arg280His (rs25489) and p.Gln399Arg (rs25487) as modifiers
of breast cancer risk in BRCA1 and BRCA2 mutation carriers. The
study was conducted in two stages, the first analysing the three
SNPs in 1277 mutation carries (701 in BRCA1 and 576 in BRCA2)
from three CIMBA study centres (CNIO, ICO and MBCSG). No
evidence of association was detected for c.-77C4T or p.Gln399Arg
with breast cancer risk in neither BRCA1 nor BRCA2 mutation
carriers (PX0.2). However, an association was observed between
p.Arg280His and breast cancer risk for BRCA2 mutation carriers,
with rare homozygotes at increased risk relative to common
homozygotes (HR: 22.3, 95% CI: 14.3–34, Po0.001; Table 2). The
apparent increased risk was consistent with the fact that the 280His
allele decreases DNA repair capacity (Takanami et al, 2005;
Pachkowski et al, 2006), however the analysis was based on a very
small number (N¼2) of homozygous women diagnosed at a very
early age and it was therefore essential that this result be
investigated in a larger sample set.
We therefore extended the analysis of the p.Arg280His-rs25489
SNP to 6219 carriers from 11 additional CIMBA study centres.
Results from stage II and both stages combined are summarised in
Table 2. No evidence of an association of AA vs GG homozygotes
with breast cancer risk was observed for BRCA2 mutation carriers
(HR: 0.73, 95% CI: 0.21–2.52, P¼0.6 in stage II and HR: 1.08, 95%
CI: 0.37–3.17, P¼0.9 in the combined), nor for BRCA1 mutation
carriers or all mutation carriers combined. We observed no
evidence of between-study heterogeneity for carriers of mutations
in BRCA2 (P¼0.8). There was evidence of heterogeneity in the
per-allele HR for BRCA1 mutation carriers (P¼0.006); exclusion
of subjects from potential outlier studies did not eliminated this
Table 1 Number of BRCA1 and BRCA2 mutation carriers by study
Study Country of residence BRCA1 BRCA2
Genotyping
platform
Spanish National Cancer Centre
a,b Spain and Greece
a 144 147 Taqman
Catalan Institute of Oncology
b Spain 144 177 Taqman
Hereditary Breast and Ovarian study Netherlands The Netherlands 791 308 iPlex
Epidemiological study of BRCA1 and BRCA2 mutation carriers UK and Eire 997 817 iPlex
Fox Chase Cancer Center USA 83 54 iPlex
Georgetown USA 43 35 iPlex
Helsinki Breast Cancer Study Finland 103 104 iPlex
Iceland Landspitali – University Hospital Iceland 0 133 iPlex
Kathleen Cuningham Consortium for Research into Familial Breast Cancer Australia 592 478 iPlex
Mayo Clinic USA 231 126 iPlex
Milan Breast Cancer Study Group
b Italy 413 252 Taqman
Pisa Breast Cancer Study Italy 86 56 iPlex
Swedish Breast Cancer Study Sweden 536 176 iPlex
University of Pennsylvania USA 317 153 iPlex
Total
c 4480 3016
aThe Spanish National Cancer Centre series consisted of mutation carriers from the Spanish Consortium for the Study of Genetic Modifiers of BRCA1 and BRCA2 and the
National Centre for Sensor Research Demokritos, Athens and Greece.
bSeries included in stage I of the study.
cMutation carriers that failed genotyping are not included in the
totals.
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substantially. Several sensitivity analyses were carried out (see
Materials and methods), but results did not change substantially
and so only those from the main analysis are presented in this
report.
Our results do not provide support for the hypothesis that the
three most common and putatively functional SNPs in XRCC1
modify breast cancer risk for BRCA1 and BRCA2 mutation
carriers. However, given the demonstrated interaction that exists
between the homologous recombination and BER DNA repair
pathways, additional SNPs in XRCC1 and other genes involved in
BER should be assessed as risk modifiers for BRCA1/2 mutation
carriers in future studies.
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